Inhibikase Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
Inhibikase Therapeutics, Inc. (IKT) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $72.75 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was $46.46K, a 2250.08% increase year-over-year.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was $26.29K, a 2619.03% increase year-over-year.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $16.71K.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $2.15K.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$37.25K.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Inhibikase Therapeutics, Inc. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was $104.72K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $46.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $72.75K 10-Q · filed 2026-08-11 | $89.46K derived: sum of 3 quarters · filed 2026-08-11 | $91.61K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $26.29K 10-Q · filed 2026-05-12 | $43.00K derived: sum of 2 quarters · filed 2026-08-11 | $45.15K derived: sum of 3 quarters · filed 2026-08-11 | $47.13K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $16.71K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-11 | $18.86K derived: sum of 2 quarters · filed 2026-08-11 | $20.84K derived: sum of 3 quarters · filed 2026-08-11 | $21.80K 10-Q · filed 2026-08-11 | $0.00 10-K · filed 2026-03-26 |
| 2025-09-30 | $2.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.13K derived: sum of 2 quarters · filed 2025-11-14 | $5.09K 10-Q · filed 2025-11-14 | -$32.16K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-06-30 | $1.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.94K 10-Q · filed 2025-08-14 | -$34.30K derived: sum of 3 quarters · filed 2026-03-26 | -$34.30K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2025-03-31 | $967.00 10-Q · filed 2025-05-14 | -$36.28K derived: sum of 2 quarters · filed 2026-03-26 | -$36.28K derived: sum of 3 quarters · filed 2026-03-26 | -$36.28K derived: sum of 4 quarters · filed 2026-03-26 | |
| 2024-12-31 | -$37.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$37.25K derived: sum of 2 quarters · filed 2026-03-26 | -$37.25K derived: sum of 3 quarters · filed 2026-03-26 | -$37.25K 10-K · filed 2026-03-26 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-27 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $0.00 derived: sum of 4 quarters · filed 2025-03-27 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | -$165.82K derived: sum of 4 quarters · filed 2025-03-27 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | -$165.82K derived: sum of 3 quarters · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 | $877.00 10-K · filed 2024-03-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$165.82K derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $53.88K derived: sum of 4 quarters · filed 2024-03-27 | |
| 2023-06-30 | -$165.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $53.88K derived: sum of 3 quarters · filed 2024-03-27 | ||
| 2023-03-31 | $165.82K 10-Q · filed 2023-05-15 | $219.70K derived: sum of 2 quarters · filed 2024-03-27 | |||
| 2022-12-31 | $53.88K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $104.72K 10-K · filed 2024-03-27 | |||
| 2022-09-30 | $50.84K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |